The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immunotherapy in Pharmaceuticals: T-cell receptor peptides. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

T-cell receptor peptides is a key innovation area in immunotherapy

T-cell receptors (TCRs) on T-cells play an important role in adoptive T-cell transfer by recognising peptides presented on the major histocompatibility complex (MHC). Antigens are processed endogenously within cells, followed by efficient binding of peptides to MHC molecules and presentation of antigenic peptides on the cell surface. Foreign and neoantigen peptides presented on the cell surface of MHC molecules are recognised by cytotoxic T cells and specifically induce cell death of infected or tumour cells. Recognition is mediated by heterodimeric cell surface TCRs present on T-cells. This TCR has highly variable alpha and beta chains. The somatic recombination process that occurs during thymic maturation results in diverse alpha and beta TCR chains, resulting in a large repertoire of unique TCRs that provide broad pathogen and tumour recognition.

GlobalData’s analysis uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 170+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of T-cell receptor peptides.

Key players in T-cell receptor peptides – an innovative target for therapies in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to T-cell receptor peptides

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Bristol-Myers Squibb 437 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 349 Unlock Company Profile
Cellectis 305 Unlock Company Profile
Fred Hutchinson Cancer Research Center 258 Unlock Company Profile
bluebird bio 249 Unlock Company Profile
City of Hope 238 Unlock Company Profile
Autolus 221 Unlock Company Profile
Gilead Sciences 216 Unlock Company Profile
Miltenyi Biotec 181 Unlock Company Profile
CARsgen Therapeutics 160 Unlock Company Profile
Eureka Therapeutics 147 Unlock Company Profile
Seattle Children's Hospital 144 Unlock Company Profile
CRISPR Therapeutics 119 Unlock Company Profile
Amgen 116 Unlock Company Profile
Pfizer 100 Unlock Company Profile
United States Of America 99 Unlock Company Profile
BioNTech 91 Unlock Company Profile
Sangamo Therapeutics 83 Unlock Company Profile
Allogene Therapeutics 71 Unlock Company Profile
Nanjing Legend Biotech 65 Unlock Company Profile
iCell Gene Therapeutics 59 Unlock Company Profile
ImmunityBio 58 Unlock Company Profile
Precigen 55 Unlock Company Profile
Innovative Cellular Therapeutics 55 Unlock Company Profile
Massachusetts General Hospital 55 Unlock Company Profile
TCR2 Therapeutics 54 Unlock Company Profile
Poseida Therapeutics 54 Unlock Company Profile
F. Hoffmann-La Roche 53 Unlock Company Profile
Genscript Biotech 50 Unlock Company Profile
Regeneron Pharmaceuticals 49 Unlock Company Profile
CytoImmune Therapeutics 48 Unlock Company Profile
EXUMA Biotech 48 Unlock Company Profile
TRON gGmbH 48 Unlock Company Profile
Immatics 47 Unlock Company Profile
Johnson & Johnson 41 Unlock Company Profile
Bellicum Pharmaceuticals 36 Unlock Company Profile
Georg-Speyer-Haus 36 Unlock Company Profile
Sorrento Therapeutics 34 Unlock Company Profile
Nkarta 33 Unlock Company Profile
Takeda Pharmaceutical 33 Unlock Company Profile
Intima Bioscience 31 Unlock Company Profile
US Department of Health and Human Services 31 Unlock Company Profile
PPF Group 30 Unlock Company Profile
NanHua Bio-Medicine 30 Unlock Company Profile
BioAtla 30 Unlock Company Profile
Alpine Immune Sciences 30 Unlock Company Profile
Editas Medicine 29 Unlock Company Profile
Arcellx 29 Unlock Company Profile
Utilities Service Alliance 29 Unlock Company Profile
GSK 29 Unlock Company Profile

Source: GlobalData Patent Analytics

Bristol-Myers Squibb (BMS) is the leading patent filer in T-cell receptor peptides. BMS is engaged in the development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is oncology, cardiovascular, immunology, and fibrotic therapeutic projects. BMS is headquartered in New York City, New York.

In terms of application diversity, Lonza Group is the top company, followed by Glycostem Therapeutics and Immatics. By means of geographic reach, Instil Bio holds the top position. Les Laboratoires Servier SAS and Intellia Therapeutics stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.